Explore more publications!

Press Releases

Russia Issues Warning to Japan Over Ukraine Arms Supplies

Russia Issues Warning to Japan Over Ukraine Arms Supplies

Over 600 Affected by Food Poisoning in Japan Schools

Over 600 Affected by Food Poisoning in Japan Schools

Valentine’s Matcha Launches with Premium Japanese Matcha for Cooking, Baking and Daily Drink Rituals
Tower Semiconductor and Nuvoton Technology Corporation Japan Announce Strategic Business Restructuring of TPSCo
Tower Semiconductor Announces Plans to Expand 300mm Capacity in Japan to Support Strong Customer Demand
President Lai meets Japan-Taiwan Friendship Association Chairman Eto Seishiro

President Lai meets Japan-Taiwan Friendship Association Chairman Eto Seishiro

Amogy and Hoku Infrastructure Partner to Advance Ammonia-to-Power Projects for Data Centers in Japan
X Refuses Japan’s Appeal to Lengthen Data Storage Period

X Refuses Japan’s Appeal to Lengthen Data Storage Period

ai& Launches with $50M Seed Round, $2B Infrastructure Capital to Scale a Vertically Integrated AI Platform from Japan
South Korea Lodges Protest Over Japan’s Renewed Islet Claims

South Korea Lodges Protest Over Japan’s Renewed Islet Claims

povo Adds New Plans to Data-Only eSIM 'Japan SIM' Lineup for international Visitors to Japan
povo Adds New Plans to Data-Only eSIM 'Japan SIM' Lineup for international Visitors to Japan
Multilingual Houwa Video from Japan’s H1 Houwa Grand Prix to Premiere Worldwide on YouTube on April 1
Professional Diversity Network, Inc. Establishes Japanese Subsidiary Colorful Japan Co., Ltd., Accelerating Strategic Expansion into RWA Entertainment Ecosystem
Beyond the Northern Sea Route: The Developmental State and Japanese Arctic Energy Policy

Beyond the Northern Sea Route: The Developmental State and Japanese Arctic Energy Policy

Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
Crypto Poker No Deposit Bonus 2026: BC Poker Offers $5 Free Bonus on Sign-Up with App Download, Real Money Tables & Instant Crypto Payouts
Nuclear Medicine Market Size to Hit US$ 28.6 Bn by 2033, Expanding at 11.2% CAGR | Persistence Market Research
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions